{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T19:17:18Z","timestamp":1774379838237,"version":"3.50.1"},"reference-count":166,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1041897, 1080045"],"award-info":[{"award-number":["1041897, 1080045"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Victorian operational infrastructure support program","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Direct-acting antiviral agents have proven highly effective at treating existing hepatitis C infections but despite their availability most countries will not reach the World Health Organization targets for elimination of HCV by 2030. A prophylactic vaccine remains a high priority. Whilst early vaccines focused largely on generating T cell immunity, attention is now aimed at vaccines that generate humoral immunity, either alone or in combination with T cell-based vaccines. High-resolution structures of hepatitis C viral glycoproteins and their interaction with monoclonal antibodies isolated from both cleared and chronically infected people, together with advances in vaccine technologies, provide new avenues for vaccine development.<\/jats:p>","DOI":"10.3390\/v13050805","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T05:10:55Z","timestamp":1619759455000},"page":"805","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity"],"prefix":"10.3390","volume":"13","author":[{"given":"Felicia","family":"Schlotthauer","sequence":"first","affiliation":[{"name":"Viral Entry and Vaccines Group, Burnet Institute, Melbourne, VIC 3004, Australia"},{"name":"Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6287-684X","authenticated-orcid":false,"given":"Joey","family":"McGregor","sequence":"additional","affiliation":[{"name":"Viral Entry and Vaccines Group, Burnet Institute, Melbourne, VIC 3004, Australia"},{"name":"Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0042-6277","authenticated-orcid":false,"given":"Heidi E","family":"Drummer","sequence":"additional","affiliation":[{"name":"Viral Entry and Vaccines Group, Burnet Institute, Melbourne, VIC 3004, Australia"},{"name":"Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia"},{"name":"Department of Microbiology, Monash University, Clayton, VIC 3800, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e25360","DOI":"10.1002\/jia2.25360","article-title":"Hepatitis C virus elimination: Time for disruptive innovation","volume":"22","author":"Klein","year":"2019","journal-title":"J. Int. AIDS Soc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12916-019-1411-9","article-title":"The case for a universal hepatitis C vaccine to achieve hepatitis C elimination","volume":"17","author":"Scott","year":"2019","journal-title":"BMC Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJM199212313272702","article-title":"The Natural History of Community-Acquired Hepatitis C in the United States","volume":"327","author":"Alter","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes","volume":"218","author":"Borgia","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20021756","article-title":"Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1\u2013E2 Envelope Protein Complexes","volume":"197","author":"Bartosch","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0014-5793(03)00635-5","article-title":"Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins","volume":"546","author":"Drummer","year":"2003","journal-title":"FEBS Lett."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrmicro3098","article-title":"The ins and outs of hepatitis C virus entry and assembly","volume":"11","author":"Lindenbach","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1128\/JVI.02198-06","article-title":"Transmembrane Domains of Hepatitis C Virus Envelope Glycoproteins: Residues Involved in E1E2 Heterodimerization and Involvement of These Domains in Virus Entry","volume":"81","author":"Ciczora","year":"2006","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1423-0127-16-89","article-title":"Mutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: Involvement in cell fusion and virus entry","volume":"16","author":"Li","year":"2009","journal-title":"J. Biomed. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8752","DOI":"10.1128\/JVI.02642-06","article-title":"Characterization of Fusion Determinants Points to the Involvement of Three Discrete Regions of Both E1 and E2 Glycoproteins in the Membrane Fusion Process of Hepatitis C Virus","volume":"81","author":"Lavillette","year":"2007","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1099\/vir.0.82567-0","article-title":"Mutagenesis of a conserved fusion peptide-like motif and membrane-proximal heptad-repeat region of hepatitis C virus glycoprotein E1","volume":"88","author":"Drummer","year":"2007","journal-title":"J. Gen. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1073\/pnas.1114927109","article-title":"Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus","volume":"109","author":"Giang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Colbert, M.D., Flyak, A.I., Ogega, C.O., Kinchen, V.J., Massaccesi, G., Hernandez, M., Davidson, E., Doranz, B.J., Cox, A.L., and Crowe, J.E. (2019). Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2. J. Virol., 93.","DOI":"10.1128\/JVI.02070-18"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1128\/JVI.01872-07","article-title":"Isolation and Characterization of Broadly Neutralizing Human Monoclonal Antibodies to the E1 Glycoprotein of Hepatitis C Virus","volume":"82","author":"Meunier","year":"2007","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9584","DOI":"10.1128\/JVI.02782-06","article-title":"Expression and Characterization of a Minimal Hepatitis C Virus Glycoprotein E2 Core Domain That Retains CD81 Binding","volume":"81","author":"McCaffrey","year":"2007","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1128\/JVI.00029-06","article-title":"A Conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr Motif in Hepatitis C Virus Glycoprotein E2 Is a Determinant of CD81 Binding and Viral Entry","volume":"80","author":"Drummer","year":"2006","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1042\/BJ20110868","article-title":"Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidines of HCV glycoprotein E1 and E2","volume":"443","author":"Boo","year":"2012","journal-title":"Biochem. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1128\/JVI.00271-06","article-title":"Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding","volume":"80","author":"Owsianka","year":"2006","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1126\/science.1243876","article-title":"Hepatitis C Virus E2 Envelope Glycoprotein Core Structure","volume":"342","author":"Kong","year":"2013","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11905","DOI":"10.1128\/JVI.01548-10","article-title":"Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Proteins Incorporated into Infectious Virions","volume":"84","author":"Helle","year":"2010","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1128\/JVI.00127-07","article-title":"The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein","volume":"81","author":"Helle","year":"2007","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8400","DOI":"10.1128\/JVI.79.13.8400-8409.2005","article-title":"Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Glycoproteins","volume":"79","author":"Goffard","year":"2005","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1128\/JVI.05396-11","article-title":"Role of Conserved Cysteine Residues in Hepatitis C Virus Glycoprotein E2 Folding and Function","volume":"86","author":"McCaffrey","year":"2012","journal-title":"J. Virol."},{"key":"ref_25","first-page":"381","article-title":"Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2","volume":"509","author":"Khan","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e53169","DOI":"10.7554\/eLife.53169","article-title":"An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein","volume":"9","author":"Flyak","year":"2020","journal-title":"eLife"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.chom.2018.10.009","article-title":"HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design","volume":"24","author":"Flyak","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"eabb5642","DOI":"10.1126\/sciadv.abb5642","article-title":"An alternate conformation of HCV E2 neutralizing face as an additional vaccine target","volume":"6","author":"Tzarum","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"31984","DOI":"10.1074\/jbc.M111.269605","article-title":"Hepatitis C Virus (HCV) Envelope Glycoproteins E1 and E2 Contain Reduced Cysteine Residues Essential for Virus Entry","volume":"286","author":"Fraser","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/hep.28989","article-title":"The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs","volume":"65","author":"Vietheer","year":"2017","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.01594-10","article-title":"Hypervariable Region 1 Differentially Impacts Viability of Hepatitis C Virus Strains of Genotypes 1 to 6 and Impairs Virus Neutralization","volume":"85","author":"Prentoe","year":"2010","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1128\/JVI.78.9.4478-4486.2004","article-title":"The Hypervariable Region 1 of the E2 Glycoprotein of Hepatitis C Virus Binds to Glycosaminoglycans, but This Binding Does Not Lead to Infection in a Pseudotype System","volume":"78","author":"Basu","year":"2004","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1093\/emboj\/cdf529","article-title":"The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus","volume":"21","author":"Scarselli","year":"2002","journal-title":"EMBO J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1006\/viro.1996.0497","article-title":"A Hyperimmune Serum against a Synthetic Peptide Corresponding to the Hypervariable Region 1 of Hepatitis C Virus Can Prevent Viral Infection in Cell Cultures","volume":"223","author":"Shimizu","year":"1996","journal-title":"Virology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1128\/jvi.68.3.1494-1500.1994","article-title":"Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses","volume":"68","author":"Shimizu","year":"1994","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2006.12.008","article-title":"Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo","volume":"132","author":"Yoon","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1128\/jvi.67.7.3923-3930.1993","article-title":"Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus","volume":"67","author":"Kato","year":"1993","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.3389\/fimmu.2018.02146","article-title":"Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry","volume":"9","author":"Prentoe","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1128\/JVI.02200-09","article-title":"Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes","volume":"84","author":"Bankwitz","year":"2010","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/hep.28705","article-title":"Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity","volume":"64","author":"Prentoe","year":"2016","journal-title":"Hepatology"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Gu, J., Hardy, J., Boo, I., Vietheer, P., McCaffrey, K., Alhammad, Y., Chopra, A., Gaudieri, S., Poumbourios, P., and Coulibaly, F. (2018). Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes. J. Virol., 92.","DOI":"10.1128\/JVI.02066-17"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1128\/JVI.02458-15","article-title":"Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus","volume":"90","author":"Keck","year":"2016","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"E82","DOI":"10.1073\/pnas.1718441115","article-title":"Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms","volume":"115","author":"Mankowski","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1099\/vir.0.83065-0","article-title":"Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33","volume":"88","author":"Tarr","year":"2007","journal-title":"J. Gen. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1128\/JVI.06492-11","article-title":"Naturally Occurring Antibodies That Recognize Linear Epitopes in the Amino Terminus of the Hepatitis C Virus E2 Protein Confer Noninterfering, Additive Neutralization","volume":"86","author":"Tarr","year":"2011","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9499","DOI":"10.1073\/pnas.1202924109","article-title":"Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1","volume":"109","author":"Kong","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"13085","DOI":"10.1128\/JVI.01939-12","article-title":"Structure of Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Site 412 to 423 in Complex with Antibody AP33","volume":"86","author":"Kong","year":"2012","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1128\/JVI.02190-14","article-title":"Structural Flexibility of a Conserved Antigenic Region in Hepatitis C Virus Glycoprotein E2 Recognized by Broadly Neutralizing Antibodies","volume":"89","author":"Meola","year":"2014","journal-title":"J. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1002\/hep.28850","article-title":"Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice","volume":"64","author":"Keck","year":"2016","journal-title":"Hepatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"10117","DOI":"10.1074\/jbc.M115.643528","article-title":"Structural Basis for Penetration of the Glycan Shield of Hepatitis C Virus E2 Glycoprotein by a Broadly Neutralizing Human Antibody","volume":"290","author":"Li","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Morin, T.J., Broering, T.J., Leav, B.A., Blair, B.M., Rowley, K.J., Boucher, E.N., Wang, Y., Cheslock, P.S., Knauber, M., and Olsen, D.B. (2012). Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002895"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Babcock, G.J., Iyer, S., Smith, H.L., Wang, Y., Rowley, K., Ambrosino, D.M., Zamore, P.D., Pierce, B.G., Molrine, D.C., and Weng, Z. (2014). High-Throughput Sequencing Analysis of Post-Liver Transplantation HCV E2 Glycoprotein Evolution in the Presence and Absence of Neutralizing Monoclonal Antibody. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100325"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.jmb.2013.02.025","article-title":"Glycan Shifting on Hepatitis C Virus (HCV) E2 Glycoprotein Is a Mechanism for Escape from Broadly Neutralizing Antibodies","volume":"425","author":"Pantua","year":"2013","journal-title":"J. Mol. Biol."},{"key":"ref_54","first-page":"1047","article-title":"Human Monoclonal Antibody MBL-HCV1 Delays HCV Viral Rebound Following Liver Transplantation: A Randomized Controlled Study","volume":"13","author":"Chung","year":"2013","journal-title":"Arab. Archaeol. Epigr."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Keck, Z.-Y., Angus, A.G.N., Wang, W., Lau, P., Wang, Y., Gatherer, D., Patel, A.H., and Foung, S.K.H. (2014). Non-random Escape Pathways from a Broadly Neutralizing Human Monoclonal Antibody Map to a Highly Conserved Region on the Hepatitis C Virus E2 Glycoprotein Encompassing Amino Acids 412\u2013423. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004297"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Keck, Z.-Y., Xia, J., Wang, Y., Wang, W., Krey, T., Prentoe, J., Carlsen, T., Li, A.Y.-J., Patel, A.H., and Lemon, S.M. (2012). Human Monoclonal Antibodies to a Novel Cluster of Conformational Epitopes on HCV E2 with Resistance to Neutralization Escape in a Genotype 2a Isolate. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002653"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"12686","DOI":"10.1128\/JVI.00994-12","article-title":"Amino Acid Residue-Specific Neutralization and Nonneutralization of Hepatitis C Virus by Monoclonal Antibodies to the E2 Protein","volume":"86","author":"Duan","year":"2012","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"10690","DOI":"10.1073\/pnas.1411317111","article-title":"Discrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralization","volume":"111","author":"Deng","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"8449","DOI":"10.1073\/pnas.0703039104","article-title":"Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma","volume":"104","author":"Zhang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Keck, Z.-Y., Pierce, B.G., Lau, P., Lu, J., Wang, Y., Underwood, A., Bull, R.A., Prentoe, J., Vel\u00e1zquez-Moctezuma, R., and Walker, M.R. (2019). Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007772"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/JVI.01941-12","article-title":"Cooperativity in Virus Neutralization by Human Monoclonal Antibodies to Two Adjacent Regions Located at the Amino Terminus of Hepatitis C Virus E2 Glycoprotein","volume":"87","author":"Keck","year":"2012","journal-title":"J. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"Law","year":"2008","journal-title":"Nat. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e92872","DOI":"10.1172\/jci.insight.92872","article-title":"Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance","volume":"2","author":"Bailey","year":"2017","journal-title":"JCI Insight"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"10451","DOI":"10.1128\/JVI.05259-11","article-title":"Mapping a Region of Hepatitis C Virus E2 That Is Responsible for Escape from Neutralizing Antibodies and a Core CD81-Binding Region That Does Not Tolerate Neutralization Escape Mutations","volume":"85","author":"Keck","year":"2011","journal-title":"J. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Merat, S.J., Molenkamp, R., Wagner, K., Koekkoek, S.M., Van De Berg, D., Yasuda, E., B\u00f6hne, M., Claassen, Y.B., Grady, B.P., and Prins, M. (2016). Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165047"},{"key":"ref_66","first-page":"254ra129","article-title":"Broadly neutralizing antibodies abrogate established hepatitis C virus infection","volume":"6","author":"Dorner","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.chom.2018.10.012","article-title":"Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection","volume":"24","author":"Kinchen","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1172\/JCI130720","article-title":"Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance","volume":"129","author":"Kinchen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1128\/JVI.02475-07","article-title":"Definition of a Conserved Immunodominant Domain on Hepatitis C Virus E2 Glycoprotein by Neutralizing Human Monoclonal Antibodies","volume":"82","author":"Keck","year":"2008","journal-title":"J. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"eaav1882","DOI":"10.1126\/sciadv.aav1882","article-title":"Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies","volume":"5","author":"Tzarum","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1073\/pnas.0308527100","article-title":"Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120","volume":"101","author":"Huang","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","first-page":"418","article-title":"Rapid development of broadly influenza neutralizing antibodies through redundant mutations","volume":"516","author":"Pappas","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nsmb.1566","article-title":"Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses","volume":"16","author":"Sui","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"aab1253","DOI":"10.1126\/science.aab1253","article-title":"Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies","volume":"349","author":"Williams","year":"2015","journal-title":"Science"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1128\/JVI.00252-08","article-title":"A Point Mutation Leading to Hepatitis C Virus Escape from Neutralization by a Monoclonal Antibody to a Conserved Conformational Epitope","volume":"82","author":"Keck","year":"2008","journal-title":"J. Virol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1099\/vir.0.83386-0","article-title":"Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein","volume":"89","author":"Owsianka","year":"2008","journal-title":"J. Gen. Virol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"9224","DOI":"10.1128\/JVI.78.17.9224-9232.2004","article-title":"Hepatitis C Virus E2 Has Three Immunogenic Domains Containing Conformational Epitopes with Distinct Properties and Biological Functions","volume":"78","author":"Keck","year":"2004","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"10407","DOI":"10.1128\/JVI.74.22.10407-10416.2000","article-title":"Human Monoclonal Antibodies That Inhibit Binding of Hepatitis C Virus E2 Protein to CD81 and Recognize Conserved Conformational Epitopes","volume":"74","author":"Hadlock","year":"2000","journal-title":"J. Virol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"13199","DOI":"10.1128\/JVI.79.21.13199-13208.2005","article-title":"Analysis of a Highly Flexible Conformational Immunogenic Domain A in Hepatitis C Virus E2","volume":"79","author":"Keck","year":"2005","journal-title":"J. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"12245","DOI":"10.1128\/JVI.02070-15","article-title":"Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region","volume":"89","author":"Alhammad","year":"2015","journal-title":"J. Virol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"E6946","DOI":"10.1073\/pnas.1614942113","article-title":"Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design","volume":"113","author":"Pierce","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1126\/science.1259206","article-title":"Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies","volume":"346","author":"McGuire","year":"2014","journal-title":"Science"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1128\/JVI.01710-06","article-title":"Immunogenic and Functional Organization of Hepatitis C Virus (HCV) Glycoprotein E2 on Infectious HCV Virions","volume":"81","author":"Keck","year":"2006","journal-title":"J. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"44218","DOI":"10.1074\/jbc.M111.290783","article-title":"Affinity Maturation to Improve Human Monoclonal Antibody Neutralization Potency and Breadth against Hepatitis C Virus","volume":"286","author":"Wang","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/hep.28108","article-title":"Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine-induced neutralizing activity","volume":"62","author":"Kachko","year":"2015","journal-title":"Hepatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1073\/pnas.0902749106","article-title":"Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity","volume":"106","author":"Zhang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2004.12.018","article-title":"Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC)","volume":"42","author":"Nattermann","year":"2005","journal-title":"J. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1073\/pnas.91.4.1294","article-title":"Vaccination of chimpanzees against infection by the hepatitis C virus","volume":"91","author":"Choo","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.virol.2004.11.034","article-title":"Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells","volume":"332","author":"Brazzoli","year":"2005","journal-title":"Virology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1016\/j.vaccine.2007.08.053","article-title":"Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies","volume":"25","author":"Stamataki","year":"2007","journal-title":"Vaccine"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1016\/j.vaccine.2010.06.084","article-title":"Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults","volume":"28","author":"Frey","year":"2010","journal-title":"Vaccine"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1086\/655902","article-title":"Characterization of Antibodies Induced by Vaccination with Hepatitis C Virus Envelope Glycoproteins","volume":"202","author":"Ray","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Law, J.L.M., Chen, C., Wong, J., Hockman, D., Santer, D.M., Frey, S.E., Belshe, R.B., Wakita, T., Bukh, J., and Jones, C.T. (2013). A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1\/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059776"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Logan, M., Law, J., Wong, J.A.J.-X., Hockman, D., Landi, A., Chen, C., Crawford, K., Kundu, J., Baldwin, L., and Johnson, J. (2017). Native Folding of a Recombinant gpE1\/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG. J. Virol., 91.","DOI":"10.1128\/JVI.01552-16"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Law, J.L.M., Logan, M., Wong, J., Kundu, J., Hockman, D., Landi, A., Chen, C., Crawford, K., Wininger, M., and Johnson, J. (2018). Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine. J. Virol., 92.","DOI":"10.1128\/JVI.02141-17"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.1074\/jbc.RA120.013015","article-title":"Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine","volume":"295","author":"Center","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"eaaz6225","DOI":"10.1126\/sciadv.aaz6225","article-title":"Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines","volume":"6","author":"He","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_98","first-page":"1304","article-title":"A Nanoparticle-Based Hepatitis C Virus Vaccine with Enhanced Potency","volume":"221","author":"Yan","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"7832","DOI":"10.1021\/acs.nanolett.8b03601","article-title":"Interrogation of Antigen Display on Individual Vaccine Nanoparticles for Achieving Neutralizing Antibody Responses against Hepatitis C Virus","volume":"18","author":"Bazzill","year":"2018","journal-title":"Nano Lett."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"10486","DOI":"10.1128\/JVI.01462-16","article-title":"Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice","volume":"90","author":"Li","year":"2016","journal-title":"J. Virol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/gutjnl-2017-314870","article-title":"A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey","volume":"68","author":"Wang","year":"2017","journal-title":"Gut"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.antiviral.2018.09.005","article-title":"Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies","volume":"160","author":"Tarr","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.addr.2014.10.023","article-title":"Formulation and stabilization of recombinant protein based virus-like particle vaccines","volume":"93","author":"Jain","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nbt.2017.07.010","article-title":"Production of virus-like particles for vaccines","volume":"39","author":"Fuenmayor","year":"2017","journal-title":"New Biotechnol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Mellado","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4\u00b75 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"ref_107","unstructured":"(2017). Hepatitis B vaccines: WHO position paper\u2014July 2017. Wkly. Epidemiol. Rec., 92, 369\u2013392."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.26132","article-title":"Chimeric hepatitis B virus\/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine","volume":"57","author":"Beaumont","year":"2013","journal-title":"Hepatology"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Beaumont, E., Roch, E., Chopin, L., and Roingeard, P. (2016). Hepatitis C Virus E1 and E2 Proteins Used as Separate Immunogens Induce Neutralizing Antibodies with Additive Properties. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151626"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1111\/liv.14541","article-title":"Mixing particles from various HCV genotypes increases the HBV-HCV vaccine ability to elicit broadly cross-neutralizing antibodies","volume":"40","author":"Beaumont","year":"2020","journal-title":"Liver Int."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.vaccine.2015.01.007","article-title":"Chimeric hepatitis B virus (HBV)\/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine","volume":"33","author":"Beaumont","year":"2015","journal-title":"Vaccine"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1128\/JVI.75.5.2130-2141.2001","article-title":"Antigenicity and Immunogenicity of Novel Chimeric Hepatitis B Surface Antigen Particles with Exposed Hepatitis C Virus Epitopes","volume":"75","author":"Netter","year":"2001","journal-title":"J. Virol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/135965350701200409","article-title":"Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies","volume":"12","author":"Vietheer","year":"2007","journal-title":"Antivir. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/S0264-410X(03)00182-8","article-title":"Immunogenicity of recombinant HBsAg\/HCV particles in mice pre-immunised with hepatitis B virus-specific vaccine","volume":"21","author":"Netter","year":"2003","journal-title":"Vaccine"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.nbt.2009.01.001","article-title":"Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: Implications for the design of new vaccine strategies","volume":"25","author":"Patient","year":"2009","journal-title":"New Biotechnol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.vaccine.2018.03.036","article-title":"Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes","volume":"36","author":"Wei","year":"2018","journal-title":"Vaccine"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"8427","DOI":"10.1073\/pnas.0702162104","article-title":"Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees","volume":"104","author":"Elmowalid","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0016-5085(99)70290-8","article-title":"Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate","volume":"117","author":"Baumert","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1053\/jhep.2001.26523","article-title":"Hepatitis C virus\u2013like particles induce virus-specific humoral and cellular immune responses in mice","volume":"34","author":"Lechmann","year":"2001","journal-title":"Hepatology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/jhep.2003.50000","article-title":"Hepatitis C virus\u2013like particles combined with novel adjuvant systems enhance virus-specific immune responses","volume":"37","author":"Qiao","year":"2003","journal-title":"Hepatology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1073\/pnas.1131929100","article-title":"Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection","volume":"100","author":"Murata","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.vaccine.2015.11.061","article-title":"Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy","volume":"34","author":"Kumar","year":"2016","journal-title":"Vaccine"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Chua, B.Y., Johnson, D., Tan, A., Earnest-Silveira, L., Sekiya, T., Chin, R., Torresi, J., and Jackson, D.C. (2012). Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047492"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1099\/jgv.0.000493","article-title":"Characterisation of a hepatitis C virus like particle vaccine produced in a human hepatocyte-derived cell line","volume":"97","author":"Chua","year":"2016","journal-title":"J. Gen. Virol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1089\/vim.2017.0182","article-title":"Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 Agonists","volume":"31","author":"Christiansen","year":"2018","journal-title":"Viral Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1038\/s41598-018-24762-9","article-title":"Immunological responses following administration of a genotype 1a\/1b\/2\/3a quadrivalent HCV VLP vaccine","volume":"8","author":"Christiansen","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"94ra71","DOI":"10.1126\/scitranslmed.3002330","article-title":"A Prime-Boost Strategy Using Virus-Like Particles Pseudotyped for HCV Proteins Triggers Broadly Neutralizing Antibodies in Macaques","volume":"3","author":"Garrone","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jviromet.2016.06.012","article-title":"Large scale production of a mammalian cell derived quadrivalent hepatitis C virus like particle vaccine","volume":"236","author":"Christiansen","year":"2016","journal-title":"J. Virol. Methods"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-45461-z","article-title":"Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery","volume":"9","author":"Christiansen","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2013.05.007","article-title":"Neutralizing Antibodies Induced by Cell Culture\u2013Derived Hepatitis C Virus Protect Against Infection in Mice","volume":"145","author":"Akazawa","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2016-312208","article-title":"Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model","volume":"67","author":"Yokokawa","year":"2016","journal-title":"Gut"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"115ra2","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nm1353","article-title":"A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees","volume":"12","author":"Folgori","year":"2006","journal-title":"Nat. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"115ra1","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJMoa2023345","article-title":"Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection","volume":"384","author":"Page","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2017.10.079","article-title":"The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes","volume":"36","author":"Donnison","year":"2018","journal-title":"Vaccine"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nat. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1128\/JVI.03574-13","article-title":"Combined Adenovirus Vector and Hepatitis C Virus Envelope Protein Prime-Boost Regimen Elicits T Cell and Neutralizing Antibody Immune Responses","volume":"88","author":"Chmielewska","year":"2014","journal-title":"J. Virol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.antiviral.2017.07.015","article-title":"Immunogenicity of an influenza virus-vectored vaccine carrying the hepatitis C virus protein epitopes in mice","volume":"145","author":"Zhang","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_142","first-page":"1","article-title":"Keyhole Limpet Hemocyanin-Conjugated Peptides from Hepatitis C Virus Glycoproteins Elicit Neutralizing Antibodies in BALB\/c Mice","volume":"2021","author":"Deng","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e01032-17","DOI":"10.1128\/JVI.01032-17","article-title":"Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope","volume":"91","author":"Pierce","year":"2017","journal-title":"J. Virol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1016\/j.vaccine.2008.03.032","article-title":"A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection","volume":"26","author":"Chua","year":"2008","journal-title":"Vaccine"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1186\/s12879-019-4571-5","article-title":"A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice","volume":"19","author":"Dawood","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.1016\/j.vaccine.2020.08.066","article-title":"A bivalent HCV peptide vaccine elicits pan-genotypic neutralizing antibodies in mice","volume":"38","author":"Mosa","year":"2020","journal-title":"Vaccine"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1177\/135965350601100809","article-title":"Exploiting information inherent in binding sites of virus-specific antibodies: Design of an HCV vaccine candidate cross-reactive with multiple genotypes","volume":"11","author":"Grollo","year":"2006","journal-title":"Antivir. Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1086\/515613","article-title":"First Human Trial of a DNA-Based Vaccine for Treatment of Human Immunodeficiency Virus Type 1 Infection: Safety and Host Response","volume":"178","author":"MacGregor","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1016\/S0264-410X(99)00094-8","article-title":"Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device","volume":"17","author":"Tacket","year":"1999","journal-title":"Vaccine"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0264-410X(99)00407-7","article-title":"Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers","volume":"18","author":"Le","year":"2000","journal-title":"Vaccine"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0065-2660(05)55002-8","article-title":"Human Clinical Trials of Plasmid DNA Vaccines","volume":"55","author":"Liu","year":"2005","journal-title":"Adv. Genet."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1128\/JVI.75.9.4040-4047.2001","article-title":"West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses In Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-Linked Immunosorbent Assays","volume":"75","author":"Davis","year":"2001","journal-title":"J. Virol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vetimm.2015.11.003","article-title":"Cancer immunology and canine malignant melanoma: A comparative review","volume":"169","author":"Atherton","year":"2016","journal-title":"Veter Immunol. Immunopathol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/S0264-410X(98)00448-4","article-title":"DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface","volume":"17","author":"Forns","year":"1999","journal-title":"Vaccine"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/jhep.2000.9877","article-title":"Vaccination of Chimpanzees With Plasmid DNA Encoding the Hepatitis C Virus(HCV) Envelope E2 Protein Modified the Infection After Challenge With Homologous Monoclonal HCV","volume":"32","author":"Forns","year":"2000","journal-title":"Hepatology"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/JVI.78.1.187-196.2004","article-title":"Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response","volume":"78","author":"Rollier","year":"2004","journal-title":"J. Virol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/hep.21573","article-title":"Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity","volume":"45","author":"Rollier","year":"2007","journal-title":"Hepatology"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/gt.2016.55","article-title":"T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates","volume":"23","author":"Rollier","year":"2016","journal-title":"Gene Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2013.09.061","article-title":"Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys","volume":"155","author":"Barouch","year":"2013","journal-title":"Cell"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/imr.12516","article-title":"Polyvalent vaccine approaches to combat HIV-1 diversity","volume":"275","author":"Korber","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1080\/21645515.2017.1380137","article-title":"Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines","volume":"13","author":"Wang","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1172\/JCI128699","article-title":"DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial","volume":"129","author":"Rouphael","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1093\/cid\/ciaa640","article-title":"Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine","volume":"71","author":"Cox","year":"2020","journal-title":"Clin. Infect. Dis."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/5\/805\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:55:52Z","timestamp":1760162152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/5\/805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":166,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["v13050805"],"URL":"https:\/\/doi.org\/10.3390\/v13050805","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,30]]}}}